Feed GILD
GI

Gilead Sciences

GILD · NASDAQ

$143.72 -1.05% (-$1.52)
1M +3.87%
Market Cap $179.8B
P/E Ratio -
Div. Yield 2.22%
ROE 16.28%

Bulios Fair Price

$138.78

3.4% downside

Preț actual

$143.72

Subevaluat Valoare justă Supraevaluat

Potrivit Bulios Fair Price, acțiunile GILD se tranzacționează în prezent aproape de valoarea lor justă. Cum funcționează?

Bulios Fair Price este o estimare a valorii corecte a unei acțiuni din modelul de evaluare Bulios. Este un punct de plecare pentru propria analiză, nu o recomandare de investiții. Cum funcționează?

Piotroski F-Score Moderate
5/9
Valuation
45 /100
Fair
EV/EBITDA 318.96x
P/S 5.90x
P/B 15.20x
Growth
56 /100
Stable
EPS growth 23.04%
Rev. growth 2.57%
FCF growth 4.26%
Profitability
50 /100
Moderate
Gross margin 79.59%
Net margin 10.64%
Op. margin 4.90%
Quality
8 /100
Poor
ROIC 6.07%
ROE 16.28%
ROA 6.56%
Debt
12 /100
High
Debt/Equity 2.22x
Current ratio 1.27x
Int. coverage -1.43x
Stability
54 /100
Moderate
Beta 0.35x
Rev. volatility 3.33%
EPS volatility 993.66%

Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe

Întreabă StockBot despre GILD
Online

Despre companie

Gilead Sciences, Inc. (GILD) is an American biopharmaceutical company specializing in research, development, and manufacturing of pharmaceuticals in the field of infectious diseases, viral diseases, and chronic conditions, such as HIV/AIDS, hepatitis C, hepatitis B, and more. The company is renowned for its innovative treatment approaches and drugs that have a significant impact on improving the quality of life for patients worldwide. Gilead Sciences is actively engaged in research and collaborates with academic institutions and healthcare organizations to discover new therapies and medications. With successful products and a strong research background, Gilead Sciences, Inc. has the potential for further innovations and expanding its pharmaceutical portfolio. Investing in Gilead Sciences, Inc. (GILD) shares may present an interesting choice for investors who follow the pharmaceutical sector and seek a company with a track record of successful products and commitment to combating serious diseases.

Nu este încă disponibil în limba dumneavoastră, așa că textul este în engleză.

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Daniel O'Day

Employees

17,000

Headquarters

Foster City

Evenimente viitoare

15 SEPT.

Ex-Dividend

Ex-dividend date

2d
29 SEPT.

Dividend Payment

Data plății

16d
29 OCT.

Earnings

Upcoming earnings report

46d

Folosim cookie-uri esențiale pentru funcționarea site-ului și cookie-uri analitice opționale pentru a măsura utilizarea. Consultați Politica de confidențialitate.